All
News
Media Coverage
Events
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
2022/11/14
LumiraDx Reports Third Quarter 2022 Results
2022/11/09
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
2022/11/02
Supporting antimicrobial stewardship using point of care CRP testing
2022/11/22
Online Webinar
51st SVA Davos Congress 2022 (Schweiz. Verband Medizinischer Praxis-Fachpersonen)
2022/11/04
Switzerland
52. Kongress für Allgemeinmedizin
2022/11/24
Austria
13th Annual Meeting of the Austrian Association for Emergency Medicine (AAEM)
Vienna, Austria
DDG Autumn Conference (Herbsttagung der Deutschen Diabetes Gesellschaft, DDG e.V.)
2022/11/25
Germany
DELAB conference
2022/10/27
Mainz, Germany
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
2022/10/12
54th Brazilian Congress of Clinical Pathology/Laboratory Medicine
2022/10/04
Brazil
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
2022/09/22
Medical Product Outsourcing: Integrating Point of Care to Future Proof our Community Health System
2022/09/16
LumiraDx Awarded Rapid Testing Agreement with Premier, Inc.
2022/09/08
KevinMD: Immediate, accurate diagnosis is crucial to the future of equitable patient care
2022/08/29
Health Tech World: LumiraDx COVID-19 antigen test alone in exceeding WHO target in Cochrane Review
2022/08/25
Health Europa: LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
MEDICA – World Forum for Medicine
Düsseldorf, Germany
LumiraDx Reports Second Quarter 2022 Results
2022/08/18
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18 2022
2022/08/12
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
2022/07/21
LumiraDx to Present on Impact of its Next-Generation Microfluidic Technology at American Association for Clinical Chemistry (AACC) Annual Conference in Chicago
2022/07/25
LumiraDx Announces Proposed Public Offering of Common Shares
2022/07/19
Nordcoag 2022
2022/08/31
Iceland
London Loves Business: Groundbreaking Covid test gives lifeline to businesses as cases soar
2022/06/30
HealthTech World: The versatile diagnostic platform that passes the test
2022/06/14
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
2022/06/09
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
2022/06/08
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
2022/06/02
360Dx: LumiraDx Gets New, Expanded CE Marks for Point-of-Care Cardiovascular Disease Tests
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
2022/05/26
Medical Device Network: LumiraDx’s HbA1c test receives CE mark for diabetes screening
HealthTech World: LumiraDx receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
MD+DI: LumiraDx Scores CE Mark for Fast POC COVID-19 Test
2022/05/24
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
2022/05/20
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
2022/05/19
HealthTech World: Antimicrobial resistance: New guidance on using CRP tests in primary care to reduce antibiotic overprescribing
2022/05/18
Annual conference paediatrics switzerland 2022 (Jahrestagung pädiatrie schweiz 2022)
Luzern, Switzerland
Annual Meeting of the Swiss Society for Clinical Chemistry (SSCC)
2022/09/14
Olma St. Gallen, Switzerland
ÖGARI (Austrian Society for Anaesthesiology, Resuscitation and Intensive Care Medicine)
2022/10/01
St. Gilgen, Austria
LumiraDx Reports First Quarter 2022 Results
2022/05/11
Bill Gates Ted Talk: We Can Make COVID-19 the Last Pandemic | Bill Gates | TED
2022/04/29
Health Europa: Answering healthcare needs with point-of-care testing
2022/04/26
Forbes: Could The Innovation Stack Revolutionize Your Industry?
2022/04/15
Fast Company: Bill Gates wants to create a global pandemic first response team
2022/04/12
6th SGAIM Autumn Congress (Herbstkongress der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, SGAIM)
Davos, Switzerland
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
2022/03/10
SeaTrade Cruise Global 2022
Miami Beach, FL USA
USCAP 2022
2022/03/23
Los Angeles, CA, USA
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
2022/03/01
LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete
2022/02/21
Health Europa: LumiraDx: Fighting antimicrobial resistance with innovative POC testing
2022/01/26
HICC Workshop 2022
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
2022/01/14
XLIX Congresso Nazionale AMCLI
2022/02/26
Italy
LumiraDx CRP Test Achieves CE Marking
2022/01/11
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B MicrofluidicAntigen Test
NHS ConfedExpo 2022
2022/06/15
UK
IBMS 2022
2022/03/14
The Pharmacy Show 2022
2022/10/16
International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress
2022/07/09
3rd Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference 2022
The 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine - EuroMedLab
2022/04/10
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
2021/12/23
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
2021/12/15
The 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2022/04/23
Portugal
FDA Reissues LumiraDx Fast Lab Solutions’ EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
2021/12/01
Medlab Middle East
2022/01/24
Dubai
AACC 2022
2022/07/24
USA
LumiraDx Monitoring of New and Emerging Variants of Concern and Detection of the Omicron Variant
2021/11/29
Scientific Spring Meeting KNVM & NVMM 2022
2022/04/05
Netherlands
6th SGAIM Spring Congress (Frühlingskongress der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, SGAIM)
2022/06/01
SSM Annual Meeting and Assembly 2022 (Swiss Society for Microbiology)
2022/08/30
51st BVKJ Annual Meeting (German Association of Pediatricians e.V.)
2022/06/17
56th DDG Annual Meeting (German Diabetes Association e.V.)
2022/05/25
Quadrimed
2022/04/28
LumiraDx Reports Third Quarter 2021 Financial Results
2021/11/10
88th DGK Annual Congress 2022
2021/04/20
5th Munich POCT Symposium (5. Münchner POCT-Symposium)
2022/09/27
11. JHaS Congress
2022/04/08
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
2021/11/02
LabLt 2021
2021/11/23
Finland
Labquality Days
2022/04/20
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
2021/10/20
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
2021/10/15
360Dx: Post-IPO, LumiraDx Pushes Adoption of POC Instrument, Eyes Test Menu Expansion
2021/10/07
360Dx: Point-of-Care Test Developer LumiraDx Goes Public on Nasdaq
2021/09/29
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
2021/09/28
Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19
2021/09/21
10th Eastern Swiss Emergency Symposium
2022/09/28
KHM-Congress 2022 (Kollegium für Hausarztmedizin)
The American College of Emergency Physicians (ACEP) Scientific Assembly 2021
2021/10/25
US
31st Graz Training Days of the Medical Association for Styria
24th CMPR Continuing Education Symposium
2022/06/16
The Pharmacy Show
2021/10/17
Birmingham
34th World Congress of Biomedical Laboratory Science
2021/08/28
Copenhagen
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
2021/08/20
PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate
2021/08/18
11th ARAM Romand Congress
Montreux, Switzerland
German Company Doctors Congress 2022 (Deutscher Betriebsärzte Kongress 2022)
2022/10/06
Weimar, Germany
Diagnostics-4-Future Conference 2022
Konstanz, Germany
Deutscher Kongress für Laboratoriumsmedizin, DKLM
2022/10/13
Mannheim, Germany
47. practica
2022/10/19
Bad Orb, Germany
32. Grazer Fortbildungstage der Ärztekammer für Steiermark
Graz, Austria
Swiss Symposium in Point of care Diagnostics
2022/10/20
Basel, Switzerland
IFAS 2022
2022/09/25
Zürich, Switzerland
DGK Heart Days (Herztage der Herz- und Kreislaufforschung, DGK e.V.)
2022/09/29
World Conference Center Bonn, Germany
LumiraDx Receives FDA Emergency Use Authorization for its COVID-19 Antibody Test, Now Allowing COVID-19 Antigen and Antibody Testing on a Single Point of Care Platform
2021/08/05
LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test
2021/07/09
LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete
2021/07/02
LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta
2021/06/24
LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries
2021/06/17
Diagnostics-4-Future Conference 2021
DGINA Annual Meeting (German Society for Interdisciplinary Emergency and Acute Medicine e.V.)
2021/11/11
SGAIM Autumn Congress
2021/09/16
EUSEM - The European Emergency Medicine Congress
2021/10/27
The European Association for the Study of Diabetes (EASD) 57th Annual Meeting
2021/09/27
Virtual
Shionogi Announces Agreement of Joint Sales with LumiraDx Japan for Novel Coronavirus Antigen test agent and diagnostic instrument in Japan
2021/04/21
The Association of Public Health Laboratories (APHL) Annual Conference
2021/05/04
LumiraDx Receives Reissued FDA Emergency Use Authorization for Its High Sensitivity, Rapid COVID-19 Molecular Lab Test
2021/04/13
Know Thrombosis – National Thrombosis Week Virtual Event
2021/05/03
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp
2021/04/07
Bloomberg: Test Maker LumiraDx to Go Public in $5 Billion SPAC Deal
2021/04/06
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
2021/01/21
SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients
2021/01/13
LumiraDx Receives Authorization by Switzerland´s Federal Office of Public Health
2020/12/21
Global Partnership to Introduce a Connected, Point of Care Diagnostic Platform for COVID-19 Antigen Testing in Africa
2020/11/10
LumiraDx COVID-19 Antigen Test Achieves CE Mark
2020/08/31
LumiraDx Receives FDA Emergency Use Authorization for Point of Care COVID-19 Antigen Test
2020/08/20
DFR Annual conference (German Association for Travel Medicine, e.V.)
2021/09/17
Procurex Scotland
2020/10/27
Online
RCGP Annual Primary Care Conference & Exhibition
2021/02/11
SSCC/SGKC Annual assembly (Swiss Society of Clinical Chemistry)
2021/09/08
LumiraDx Launches first-of-its-kind smart Diagnostic platform
2019/08/29
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.